Metastatic Breast Cancer Collaborative Research Initiative
Susan G. Komen + Duke University + University of North Carolina at Chapel Hill = REAL IMPACT
The Susan G. Komen® Metastatic Breast Cancer (MBC) Collaborative Research Initiative is a first-of-its-kind collaborative effort that is bringing together the best and brightest researchers at Duke Cancer Institute and UNC Lineberger Comprehensive Cancer Center to find breakthrough discoveries to end metastatic breast cancer. Research will cure this disease. Until then, research will transform MBC from a terminal diagnosis to a chronic disease, giving patients and their families the priceless gift of time.
Thousands of families’ lives will be changed forever by an MBC diagnosis this year. Sadly, more than 44,000 lives are at risk of dying from breast cancer this year in the U.S. We need outstanding translational research into the understanding, detection, and treatment of metastatic breast cancer now.
This is the work needed today. This is the work that will enable us to find the cures. The five-year relative survival rate for metastatic breast cancer is only 29%. This is unacceptable. With your help, Komen + Duke + UNC will help change those numbers and give the ultimate gift of time to the far too many families counting on us.
Did You Know?
Although metastatic breast cancer has spread to another part of the body, it’s still breast cancer and it is treated as breast cancer.
Senior VP, Mission at Susan G. Komen
“Today, the five-year relative survival rate for metastatic breast cancer is only twenty-nine percent. There is critical need for increasing our understanding of metastatic breast cancer and developing new ways to treat those living with the disease to help them live longer, better lives.
We have a unique opportunity to support innovative research in the Triangle area through a unique collaboration between Duke University and the University of North Carolina at Chapel Hill. This approach can lead to the very breakthroughs needed to change outcomes and save lives.
We are inspired by the leadership of the Komen NC Triangle to develop and lead this game-changing initiative, and we look forward to working alongside this local collaboration to find new treatments and cures for metastatic breast cancer.”
The Metastatic Breast Cancer Collaborative Research Initiative is dedicated to funding research breakthroughs specifically for metastatic breast cancer in the labs of two of the most renowned research institutions in the world: The University of North Carolina at Chapel Hill and Duke University. Over the past 10 years, Susan G. Komen has invested more than $27 million in Triangle-based research.
Susan G. Komen and Blue Cross NC Metastatic Breast Cancer Disparities Collaborative Research Grant
MBC Research Virtual Summit Sponsor
MBC Research Partner
Susan G. Komen and Gilead Sciences, Inc for North Carolina’s Metastatic Breast Cancer Collaborative Research Grant
Spotlight Catalyst Donor
A Sole Team for Vickie
Jean S. Gross and Donald J. Miller